How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Nucleic Acid-Based Multiplex Assays Market
- By Product Type: Multiplex PCR Kits, Microarray-Based Assays, Next-Generation Sequencing (NGS) Panels, Bead-Based Multiplex Assays, Luminex Assays
- By Application: Infectious Disease Diagnosis, Genetic Disorder Screening, Oncology and Cancer Research, Pharmacogenomics, Agricultural Biotechnology
- By End User: Clinical Diagnostic Laboratories, Research Laboratories, Pharmaceutical and Biotechnology Companies, Academic and Government Research Institutes, Contract Research Organizations (CROs)
- By Technology: Real-Time PCR Multiplexing, Microarray Technology, Next-Generation Sequencing, Bead-Based Flow Cytometry, Digital PCR
- By Sample Type: Blood Samples, Tissue Biopsies, Saliva Samples, Urine Samples, Environmental Samples
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Multiplex PCR Kits leads By Product Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 307 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.186 →
- 12 Company Profiles 16 players: SWOT & benchmarking p.194 →
Full report · locked preview
Everything inside the Nucleic Acid-Based Multiplex Assays Market report
A complete, evidence-based study - 12 chapters and 129 sections covering market size, segmentation across 5 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Product Type 5
Application 5
End User 5
Technology 5
Sample Type 5
Companies profiled
Thermo Fisher Scientific
QIAGEN
Roche Diagnostics
Bio-Rad Laboratories
Agilent Technologies
Luminex Corporation
Illumina
PerkinElmer
Merck KGaA (MilliporeSigma)
Abbott Laboratories
BD (Becton
Dickinson and Company)
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Thermo Fisher Scientific
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →QIAGEN
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Roche Diagnostics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Bio-Rad Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Agilent Technologies
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Luminex Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Illumina
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →PerkinElmer
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Merck KGaA (MilliporeSigma)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Abbott Laboratories
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →BD (Becton
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Dickinson and Company)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →GenMark Diagnostics
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Hologic
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Cepheid (a Danaher company)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Fluidigm Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$1,649M by 2033 · 5.3% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Multiplex PCR Kits41.4
- Microarray-Based Assays15.7
- Next-Generation Sequencing (NGS) Panels11.7
- Bead-Based Multiplex Assays14.4
- Luminex Assays16.9
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$359.4M → $571.4M · 6.0%
Europe$250.5M → $384.4M · 5.5%
Asia Pacific$228.7M → $361.8M · 5.9%
Latin America$141.6M → $203.4M · 4.6%
Middle East and Africa$108.9M → $146.5M · 3.8%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →5.282026
5.282027
5.292028
5.312029
5.322030
5.332031
5.342032
5.352033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Thermo Fisher Scientific22.3
- QIAGEN10.3
- Roche Diagnostics13.9
- Bio-Rad Laboratories5.0
- Agilent Technologies8.5
- Luminex Corporation12.0
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Product Type15.5%
Application22.4%
End User21.2%
Technology24.3%
Sample Type16.6%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.3
- Europe23.1
- Asia Pacific21.7
- Latin America12.2
- Middle East and Africa8.8
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Thermo Fisher Scientific | 90 | 94 | 96 | 98 | 91 | 98 | 95 |
| QIAGEN | 73 | 75 | 71 | 78 | 88 | 76 | 77 |
| Roche Diagnostics | 69 | 84 | 87 | 68 | 81 | 84 | 79 |
| Bio-Rad Laboratories | 67 | 65 | 79 | 60 | 63 | 73 | 68 |
| Agilent Technologies | 59 | 69 | 73 | 70 | 71 | 74 | 69 |
| Luminex Corporation | 66 | 69 | 52 | 54 | 69 | 46 | 59 |
| Illumina | 63 | 65 | 54 | 52 | 57 | 46 | 56 |
| PerkinElmer | 52 | 40 | 46 | 49 | 52 | 45 | 47 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Thermo Fisher Scientific
- QIAGEN
- Roche Diagnostics
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| QIAGEN | ◐ | ✓ | ◐ | ◐ | ✓ | ✓ |
| Roche Diagnostics | ◐ | ✓ | ◐ | ✓ | ◐ | ◐ |
| Bio-Rad Laboratories | − | − | ◐ | ◐ | ◐ | ✓ |
| Agilent Technologies | − | ◐ | ✓ | − | ◐ | ◐ |
| Luminex Corporation | ◐ | ◐ | ◐ | − | ◐ | − |
| Illumina | ◐ | ✓ | − | − | ◐ | ◐ |
| PerkinElmer | ◐ | − | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Thermo Fisher Scientific95
2Roche Diagnostics79
3QIAGEN77
4Agilent Technologies69
5Bio-Rad Laboratories68
6Luminex Corporation59
7Illumina56
8PerkinElmer47
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Thermo Fisher ScientificRoche Diagnostics
Challenger3
Strong scale, closing on the leaders.
QIAGENBio-Rad LaboratoriesAgilent Technologies
Contender1
Focused players with pockets of strength.
Luminex Corporation
Niche2
Specialists in a single segment or region.
IlluminaPerkinElmer
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Product Type in North America, then scale across Nucleic Acid-Based Multiplex Assays Market — a $507M beachhead inside a $7.02B market.
Beachhead (SOM)$507Mobtainable near-term
Serviceable (SAM)$2.75Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion92 fit
Multiplex PCR Kits
Best fit — highest urgency & budget in Product Type.
Economic buyer75 fit
Microarray-Based Assays
Strong fit — clear ROI and a fast path to value.
End user68 fit
Next-Generation Sequencing (NGS) Panels
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Product Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Application & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel27%
Digital / self-serve23%
Marketplaces6%
Positioning & messaging
§GTM 2 · p.194 →For Product Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Nucleic Acid-Based Multiplex Assays Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified42%
Sales qualified21%
Evaluation12%
Closed-won7%
$15.0KCAC
$81KLTV
5.4:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Nucleic Acid-Based Multiplex Assays Market is a high-growth opportunity — $7.32B by 2033, compounding at 10.5%.
TAM · 2025$3.31Btoday
TAM · 2033$7.32Bforecast
CAGR10.5%2027–2033
Cumulative$45.8Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$7.32BTotal addressable market
SAM$2.71BServiceable available market
SOM$551MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →10.5% CAGR
Demand compounds through 2033, outpacing GDP across Product Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Product Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$7.32BLarge & growingTAM by 2033 at 10.5% CAGR
$2.71BServiceable nowreachable with today’s model
$551MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$5.71BBear6.8% CAGR
$7.32BBase10.5% CAGR
$9.38BBull13.8% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Application optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Nucleic Acid-Based Multiplex Assays Market — a $9.69B market by 2033. Plan: grow share from 6.1% to 11.8%.
Market size · 2033$9.69Btotal addressable
Market CAGR10.7%2027–2033
Target share11.8%from 6.1% today
Revenue ambition$1.14Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 6.1% | 11.8% | On track |
| Revenue | $603M | $1.14B | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 32.2% | 39.8% | On track |
| Customer retention | 87.0% | 95.7% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Product Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Application capability
A defensible second engine — invest in Application to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Product Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Application
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $142M capacity & capability investment
- Greenlight bolt-on M&A in Application
- Authorise North America expansion plan
- Fund R&D program for Product Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossBehind
- Input-cost & supply riskOn track
- Regulatory / policy changeBehind
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Nucleic Acid-Based Multiplex Assays Market conversation — a $1.53B market you can size, segment and defend in minutes.
Market size · 2033$1.53Btotal opportunity
Growth8.7%CAGR to 2033
Addressable buyers1,583+accounts in scope
Typical ROI5.1×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Product Type
Goal Grow share in Product Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.1×return on cost, year one
< 4 mopayback period
$89K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Thermo Fisher ScientificQIAGENRoche DiagnosticsBio-Rad LaboratoriesAgilent TechnologiesLuminex CorporationIlluminaPerkinElmer+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Nucleic Acid-Based Multiplex Assays Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Nucleic Acid-Based Multiplex Assays Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Tumor Microwave Ablation Systems Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportTumor Radiofrequency Ablation Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportMedical Practice Management (PMS) Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportAnti-Obesity Prescription Drugs Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportBrilinta Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportTicagrelor Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportOral Antiseptic Market
Market size, share, segmentation and regional forecast.
$4.9B market · 2025 base year
View reportCoenzyme A Market
Market size, share, segmentation and regional forecast.
$5.9B market · 2025 base year
View reportImmunocytokines Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportChildhood Vaccines Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportGlioblastoma Treatment Drugs Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportParenteral Drugs Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.